Saroglitazar (BioDeep_00000837980)
代谢物信息卡片
Saroglitazar
化学式: C25H29NO4S (439.1817)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCOC(CC1=CC=C(C=C1)OCCN2C(=CC=C2C3=CC=C(C=C3)SC)C)C(=O)O
InChI: InChI=1S/C25H29NO4S/c1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20/h5-14,24H,4,15-17H2,1-3H3,(H,27,28)/t24-/m0/s1
描述信息
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C154291 - Peroxisome Proliferator-Activated Receptor Agonist
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:134708
- PubChem: 60151560
- DrugBank: DB13115
- ChEMBL: CHEMBL4297530
- CAS: 495399-09-2
- medchemexpress: HY-19937
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Devaraj Ezhilarasan. Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD.
Metabolism: clinical and experimental.
2024 Jun; 155(?):155912. doi:
10.1016/j.metabol.2024.155912. [PMID: 38609038] - Ahmed E Amer, Hamdy A Ghoneim, Rania R Abdelaziz, George S G Shehatou, Ghada M Suddek. Saroglitazar mitigated NASH-associated hepatic injury in dexamethasone-treated rats via modulating autophagy, apoptosis, and necroptosis.
Toxicology and applied pharmacology.
2024 01; 482(?):116774. doi:
10.1016/j.taap.2023.116774. [PMID: 38040297] - Mohammad Shadab Siddiqui, Deven Parmar, Farheen Sheikh, Shiv Kumar Sarin, Laura Cisneros, Samer Gawrieh, Taufik Momin, Ajay Duseja, Arun J Sanyal. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
2023 09; 21(10):2597-2605.e2. doi:
10.1016/j.cgh.2023.01.018. [PMID: 36731585] - Sanjay Bandyopadhyay, Shambo Samrat Samajdar, Saibal Das. Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.
Clinics and research in hepatology and gastroenterology.
2023 08; 47(7):102174. doi:
10.1016/j.clinre.2023.102174. [PMID: 37380128] - Devarapalli Ranjani Durga, Nadella Mounika, Pravallika Mudimala, Ramu Adela. Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Clinical drug investigation.
2022 Dec; 42(12):1049-1064. doi:
10.1007/s40261-022-01219-6. [PMID: 36329293] - Rene Rodriguez-Gutierrez, Jose Gerardo González, Deven Parmar, Farheen Shaikh, Pio Cruz-López. Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial.
Journal of lipid research.
2022 07; 63(7):100233. doi:
10.1016/j.jlr.2022.100233. [PMID: 35605678] - Madhukar Saxena, S Venkatesa Prabhu, M Mohseen, Amit Kumar Pal, Saud Alarifi, Neelam Gautam, Hemalatha Palanivel. Antidiabetic Effect of Tamarindus indica and Momordica charantia and Downregulation of TET-1 Gene Expression by Saroglitazar in Glucose Feed Adipocytes and Their Involvement in the Type 2 Diabetes-Associated Inflammation In Vitro.
BioMed research international.
2022; 2022(?):9565136. doi:
10.1155/2022/9565136. [PMID: 35832850] - Mohammad Shadab Siddiqui, Michael O Idowu, Deven Parmar, Brian B Borg, Douglas Denham, Nicole M Loo, Donald Lazas, Ziad Younes, Arun J Sanyal. A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
2021 12; 19(12):2670-2672. doi:
10.1016/j.cgh.2020.10.051. [PMID: 33152542] - Soumalya Sarkar, Deepika Kumari, Sonu Kumar Gupta, Vipin Sharma, Sumedha Mukhi, Parul Kamboj, Vedula Sasibhushan, Rajiva Kumar Rai, Sastry Lakshminarayana Jatavallabhula, Dinesh Mahajan, Yashwant Kumar, Ajay Kumar, Madhu Dikshit. Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2021 Dec; 144(?):112357. doi:
10.1016/j.biopha.2021.112357. [PMID: 34794234] - Samer Gawrieh, Mazen Noureddin, Nicole Loo, Rizwana Mohseni, Vivek Awasty, Kenneth Cusi, Kris V Kowdley, Michelle Lai, Eugene Schiff, Deven Parmar, Pankaj Patel, Naga Chalasani. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
Hepatology (Baltimore, Md.).
2021 10; 74(4):1809-1824. doi:
10.1002/hep.31843. [PMID: 33811367] - Ravinder Naik Dharavath, Shiyana Arora, Kanthi Kiran Kondepudi, Mahendra Bishnoi, Kanwaljit Chopra. Saroglitazar, a novel dual PPAR-α/γ agonist, reverses high fat-low protein diet-induced metabolic and cognitive aberrations in C57BL/6J male mice.
Life sciences.
2021 Apr; 271(?):119191. doi:
10.1016/j.lfs.2021.119191. [PMID: 33571514] - Joost Boeckmans, Alessandra Natale, Matthias Rombaut, Karolien Buyl, Brent Cami, Veerle De Boe, Anja Heymans, Vera Rogiers, Joery De Kock, Tamara Vanhaecke, Robim M Rodrigues. Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists.
Cell biology and toxicology.
2021 04; 37(2):293-311. doi:
10.1007/s10565-020-09544-2. [PMID: 32613381] - Akihiro Honda, Shotaro Kamata, Chihiro Satta, Yui Machida, Kie Uchii, Kazuki Terasawa, Ayane Nemoto, Takuji Oyama, Isao Ishii. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
Biological & pharmaceutical bulletin.
2021; 44(9):1210-1219. doi:
10.1248/bpb.b21-00232. [PMID: 34471049] - Omesh Goyal, Sahil Nohria, Prerna Goyal, Jaskirat Kaur, Sarit Sharma, Ajit Sood, Rajoo Singh Chhina. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.
Scientific reports.
2020 12; 10(1):21117. doi:
10.1038/s41598-020-78342-x. [PMID: 33273703] - Deep Dutta, Saptarshi Bhattacharya, Vineet Surana, Sameer Aggarwal, Rajiv Singla, Deepak Khandelwal, Meha Sharma. Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis.
Diabetes & metabolic syndrome.
2020 Nov; 14(6):1759-1768. doi:
10.1016/j.dsx.2020.08.039. [PMID: 32937280] - Mirhan N Makled, Dalia H El-Kashef. Saroglitazar attenuates renal fibrosis induced by unilateral ureteral obstruction via inhibiting TGF-β/Smad signaling pathway.
Life sciences.
2020 Jul; 253(?):117729. doi:
10.1016/j.lfs.2020.117729. [PMID: 32348836] - Ashu Rastogi, Richard L Dunbar, Hemant P Thacker, Jayesh Bhatt, Krupi Parmar, Deven V Parmar. Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.
Acta diabetologica.
2020 Jul; 57(7):809-818. doi:
10.1007/s00592-020-01487-8. [PMID: 32030508] - Yu Yang, Yu Zhao, Wenzhen Li, Yuyao Wu, Xin Wang, Yijie Wang, Tingmei Liu, Tinghong Ye, Yongmei Xie, Zhiqiang Cheng, Jun He, Peng Bai, Yiwen Zhang, Liang Ouyang. Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment.
European journal of medicinal chemistry.
2020 Jul; 197(?):112311. doi:
10.1016/j.ejmech.2020.112311. [PMID: 32339855] - Manjunath Krishnappa, Kishor Patil, Krupi Parmar, Purav Trivedi, Nirali Mody, Chintan Shah, Khushboo Faldu, Sanjay Maroo, Deven Parmar. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
Cardiovascular diabetology.
2020 06; 19(1):93. doi:
10.1186/s12933-020-01073-w. [PMID: 32560724] - Divya P Kumar, Rebecca Caffrey, Jonathon Marioneaux, Prasanna K Santhekadur, Madhavi Bhat, Cristina Alonso, Srinivas V Koduru, Binu Philip, Mukul R Jain, Suresh R Giri, Pierre Bedossa, Arun J Sanyal. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
Scientific reports.
2020 06; 10(1):9330. doi:
10.1038/s41598-020-66458-z. [PMID: 32518275] - Joost Boeckmans, Alessandra Natale, Matthias Rombaut, Karolien Buyl, Vera Rogiers, Joery De Kock, Tamara Vanhaecke, Robim M Rodrigues. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
Cells.
2019 12; 9(1):. doi:
10.3390/cells9010037. [PMID: 31877771] - Nimisha Jain, Shobhit Bhansali, Anura V Kurpad, Meredith Hawkins, Akhilesh Sharma, Sandeep Kaur, Ashu Rastogi, Anil Bhansali. Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial.
Scientific reports.
2019 12; 9(1):19017. doi:
10.1038/s41598-019-55466-3. [PMID: 31831868] - Upendra Kaul, Deven Parmar, K Manjunath, Mitesh Shah, Krupi Parmar, Kishor P Patil, Ashok Jaiswal. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
Cardiovascular diabetology.
2019 06; 18(1):80. doi:
10.1186/s12933-019-0884-3. [PMID: 31208414] - Noha F Hassan, Somaia A Nada, Azza Hassan, Mona R El-Ansary, Muhammad Y Al-Shorbagy, Rania M Abdelsalam. Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis.
Inflammation.
2019 Jun; 42(3):1056-1070. doi:
10.1007/s10753-019-00967-6. [PMID: 30737662] - Poonam Giri, Prashant Delvadia, Meera K Ladani, Namrata Prajapati, Lakshmikant Gupta, Nirmal Patel, Vipul Joshi, Shyamkumar Giri, Mukul R Jain, Nuggehally R Srinivas, Pankaj R Patel. Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2019 Mar; 130(?):107-113. doi:
10.1016/j.ejps.2019.01.005. [PMID: 30633968] - Pitchai Balakumar, Nanjaian Mahadevan, Ramanathan Sambathkumar. A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia.
Current molecular pharmacology.
2019; 12(3):195-201. doi:
10.2174/1874467212666190111165015. [PMID: 30636619] - Harilal Patel, Poonam Giri, Prakash Patel, Sanjay Singh, Laxmikant Gupta, Urvesh Patel, Nirav Modi, Kalpesh Shah, Mukul R Jain, Nuggehally R Srinivas, Pankaj Patel. Preclinical evaluation of saroglitazar magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders.
Xenobiotica; the fate of foreign compounds in biological systems.
2018 Dec; 48(12):1268-1277. doi:
10.1080/00498254.2017.1413264. [PMID: 29224415] - Mukul R Jain, Suresh R Giri, Bibhuti Bhoi, Chitrang Trivedi, Akshyaya Rath, Rohan Rathod, Ramchandra Ranvir, Shekhar Kadam, Hiren Patel, Prabodha Swain, Sib Sankar Roy, Nabanita Das, Eshani Karmakar, Walter Wahli, Pankaj R Patel. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.
Liver international : official journal of the International Association for the Study of the Liver.
2018 06; 38(6):1084-1094. doi:
10.1111/liv.13634. [PMID: 29164820] - Shuchi N Joshi, Nuggehally R Srinivas, Deven V Parmar. Limited Sampling Strategy for Accurate Prediction of Pharmacokinetics of Saroglitazar: A 3-point Linear Regression Model Development and Successful Prediction of Human Exposure.
Clinical therapeutics.
2018 03; 40(3):456-468.e1. doi:
10.1016/j.clinthera.2018.01.016. [PMID: 29496320] - Deepak Bhosle, Vandana Bhosle, Jyoti Bobde, Abhijeet Bhagat, Huzaif Shaikh, Rajesh Kadam. Study of Saroglitazar in Treatment Of Pre-diabetes with Dyslipidemia: STOP-D.
The Journal of the Association of Physicians of India.
2018 03; 66(3):14-7. doi:
NULL. [PMID: 30341861] - Maulik R Patel, Kevinkumar A Kansagra, Devang P Parikh, Deven V Parmar, Hardik B Patel, Mayur M Soni, Uday S Patil, Harilal V Patel, Jaimik A Patel, Swagat S Gujarathi, Krupi V Parmar, Nuggehally R Srinivas. Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects.
Clinical drug investigation.
2018 Jan; 38(1):57-65. doi:
10.1007/s40261-017-0584-2. [PMID: 29022212] - Ashok Ghoghari, Ranjeet Dash, Chandrakant Bhatt, Kanchan Singh, Anil Jha, Harilal Patel, Rahul Gupta, Kevinkumar Kansagra, Nuggehally R Srinivas. Quantitative determination of saroglitazar, a predominantly PPAR alpha agonist, in human plasma by a LC-MS/MS method utilizing electrospray ionization in a positive mode.
Biomedical chromatography : BMC.
2016 Dec; 30(12):1900-1907. doi:
10.1002/bmc.3760. [PMID: 27187607] - Ashok Mandala, Nabanita Das, Sudarshan Bhattacharjee, Bidisha Mukherjee, Satinath Mukhopadhyay, Sib Sankar Roy. Thioredoxin interacting protein mediates lipid-induced impairment of glucose uptake in skeletal muscle.
Biochemical and biophysical research communications.
2016 Oct; 479(4):933-939. doi:
10.1016/j.bbrc.2016.09.168. [PMID: 27702549] - Alka Deshpande, Harsh Toshniwal, Shashank Joshi, Rajendrakumar H Jani. A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy.
PloS one.
2016; 11(1):e0146222. doi:
10.1371/journal.pone.0146222. [PMID: 26789842] - Shashank R Joshi. Saroglitazar for the treatment of dyslipidemia in diabetic patients.
Expert opinion on pharmacotherapy.
2015 Mar; 16(4):597-606. doi:
10.1517/14656566.2015.1009894. [PMID: 25674933] - Sanjay Chatterjee, Anirban Majumder, Subir Ray. Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes.
Scientific reports.
2015 Jan; 5(?):7706. doi:
10.1038/srep07706. [PMID: 25573251] - Sadanand R Shetty, Soumitra Kumar, R P Mathur, Kamal H Sharma, Ashok D Jaiswal. Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients.
Indian heart journal.
2015 Jan; 67(1):23-6. doi:
10.1016/j.ihj.2015.02.007. [PMID: 25820046] - Rajendrakumar H Jani, Vikas Pai, Pramod Jha, Gunjan Jariwala, Satinath Mukhopadhyay, Anil Bhansali, Shashank Joshi. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI).
Diabetes technology & therapeutics.
2014 Feb; 16(2):63-71. doi:
10.1089/dia.2013.0253. [PMID: 24138536] - Ritesh Agrawal. The first approved agent in the Glitazar's Class: Saroglitazar.
Current drug targets.
2014 Feb; 15(2):151-5. doi:
10.2174/13894501113149990199. [PMID: 23906191] - Rajendra H Jani, Kevinkumar Kansagra, Mukul R Jain, Harilal Patel. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.
Clinical drug investigation.
2013 Nov; 33(11):809-16. doi:
10.1007/s40261-013-0128-3. [PMID: 24062180]
